Effectiveness and safety of fexinidazole for gambiense human African trypanosomiasis and exploration of adherence in outpatients: a phase 3b, prospective, open-label, non-randomised, cohort study
Effectiveness and safety of fexinidazole for gambiense human African trypanosomiasis and exploration of adherence in outpatients: a phase 3b, prospective, open-label, non-randomised, cohort study
Médard Ilunga Wa Kyhi, Caroline Menétrey, Willy Kuziena Mindele, Wilfried Mutombo Kalonji et al.
Citations
6 citations
Journal
The Lancet Global Health
Topics
Trypanosoma species research and implications
Field-Weighted Citation Impact (FWCI)
8.13
article
Effectiveness and safety of fexinidazole for gambiense human African trypanosomiasis and exploration of adherence in outpatients: a phase 3b, prospective, open-label, non-randomised, cohort study
Médard Ilunga Wa Kyhi, Caroline Menétrey, Willy Kuziena Mindele, Wilfried Mutombo Kalonji, Christelle Perdrieu, Digas Ngolo Tete, Mamadou Camara, Bruno Scherrer, Guylain Mandula, Tim Mayala Malu, Dieudonné Mpoyi Muamba Nzambi, Victor Kande Betu Kumeso, Mariame Camara, Felix Akwaso Masa, Ansoumane Kourouma, Olaf Valverde Mordt, Serge Luwawu Ntoya, Anne Reymondier, John Tampwo, Hélène Mahenzi, Joseph Makaya, Papy Kavunga
article en
6 citations
Abstract
No abstract available for this paper.
Publication Tag
The Lancet Global HealthVol. 13(5)
Institutions
Ministry of Public Health (CD), Kinshasa General Hospital (CD), University of Bandundu (CD)
Funders
Bill and Melinda Gates Foundation, Médecins Sans Frontières, Takeda Pharmaceutical Company, Bundesministerium für Bildung und Forschung, Stavros Niarchos Foundation, Ministerie van Buitenlandse Zaken, Direktoratet for Utviklingssamarbeid, Direktion für Entwicklung und Zusammenarbeit